Abstract: Hfq is a pleiotropic regulator that has key roles in the control of genetic expression. The protein noticeably regulates translation efficiency and RNA decay in Gram-negative bacteria, due to the Hfq-mediated interaction between small regulatory noncoding RNA and mRNA. This property is of primary importance for bacterial adaptation and virulence. We have previously shown that the Hfq \textit{E. coli} protein, and more precisely its C-terminal region (CTR), self-assembles into an amyloid-like structure. In the present work, we demonstrate that epigallocatechin gallate (EGCG), a major green tea polyphenol compound, targets the Hfq amyloid region and can be used as a potential antibacterial agent. We analysed the effect of this compound on Hfq amyloid fibril stability and show that EGCG both disrupts Hfq-CTR fibrils and inhibits their formation. We show that, even if EGCG affects other bacterial amyloids, it also specifically targets Hfq-CTR in vivo. Our results provide an alternative approach for the utilisation of EGCG that may be used synergistically with conventional antibiotics to block bacterial adaptation and treat infections.

Keywords: bacterial amyloid; functional amyloid; protein fibrils; epigallocatechin gallate (EGCG); protein fibrillation inhibition; Hfq; bacterial adaptation; antibacterial

1. Introduction

Antibiotic resistance occurs when a compound has lost its ability to kill bacteria. This problem is particularly critical for public health and many efforts have been done to modify and improve existing antibiotics. Indeed, antibacterial agents use four main mechanisms; inhibition of cell wall synthesis (β-lactams), inhibition of protein synthesis (aminoglycosides, tetracyclines), inhibition of nucleic acid synthesis (quinolones) or inhibition of metabolic pathways (sulfonamides). However, the main problem with this therapeutic approach is the development of new acquired resistances. These usually involve mutations in genes of the antibiotic target or acquisition of foreign DNA, allowing antibiotic modification, destruction or efflux [1]. Therefore, the search for novel antibacterial-targets is of utmost importance.

Recent research has aimed at exploring potential targets within proteins involved in the regulation of the genetic expression. This includes proteins involved in bacterial adaptation to their host...
environment during infection, promoting their dissemination inside the organism. For instance expression of some virulence factors is switched on when the pathogen penetrates inside the host environment [2]. Such an adaptation allows the infection to progress and bacteria to proliferate. To achieve this goal, bacteria usually operate at two main levels of gene expression regulation: (i) regulation at the transcriptional level. Nucleoid-associated proteins for instance are involved in the maintenance of bacterial chromosomal architecture. They affect the expression of a large number of genes, most coding for housekeeping-proteins, but also for proteins involved in response to environmental changes induced during host colonisation [3–6]; (ii) regulation at the post-transcriptional level [7]. One of the most promising approaches in this direction consists in blocking noncoding RNA-based (ncRNA) regulation [8,9]. Many ncRNA from different bacterial species have been identified. They are on average 100 nucleotides long, hence their name of small RNA (sRNA) [10,11]. In Gram-negative bacteria, sRNA often functions by base pairing within regions around the translation initiation signal of the associated mRNA target, and therefore acts on both mRNA translation and stability [12]. In vivo, a protein called Hfq is required for this sRNA-regulation as it promotes annealing of the regulatory sRNA to its cognate mRNA [13,14]. Due to the diversity of their mRNA targets, sRNA and Hfq are thus involved in important bacterial cell processes, including virulence, quorum sensing and pathogenicity [15–17]. Taking into account the crucial role of this protein in the adaptation to the host environment, blocking Hfq function may depress Gram-negative bacterial adaptive capacity, including resistance to antibiotics [18,19]. Efforts have thus been made to block Hfq function in order to affect bacterial virulence [19].

Interestingly, Hfq is structurally related to the Sm eukaryotic family of proteins, which participates in RNA-related processes such as splicing, decapping and decay [20,21]. Indeed, the amino-terminal region of Hfq (NTR, about 65 amino acid residues) folds similarly to Sm proteins. This region comprises a bent antiparallel β-sheet, capped by an N-terminal α-helix. The β-sheets from six monomers interact with each other to assemble in a hexameric toroidal structure [22,23]. It is established that the inner pore on the proximal face of the NTR torus (on which the α-helix is present) binds U-rich RNA, while A-rich sequences bind to the distal face [24–26]. Attempts have already been made to block Hfq-NTR interaction with sRNA, in order to affect virulence [19]. Nevertheless, besides its Sm-like domain, the Hfq C-terminal region (CTR) also plays a role in nucleic acid recognition [27,28]. While numerous 3D-structures of various Hfq have been resolved [25,26,29–32], until now all lack the CTR, and the way this region folds remains unknown [23]. It has however been shown that Hfq CTR is able to self-assemble into an amyloid-like structure [33,34]. Furthermore, this amyloid-like region dictates Hfq cellular location, namely at the periphery of the bacterial cell, near the inner membrane [34–36]. Almost one half of Hfq-binding sRNAs with known targets regulate the expression of membrane proteins [37], allowing exchange with the extracellular environment. Therefore Hfq self-assembly, which targets Hfq to the membrane, may be of primary importance for its role in bacterial cell adaptation [38]. We thus hypothesize that interfering with the formation of the Hfq-CTR amyloid structure may have direct consequence for bacterial survival.

Epigallocatechin-3-gallate (EGCG) is the major polyphenolic catechin found in green tea (Camellia sinensis). EGCG has been shown to inhibit fibrillation of amyloidogenic proteins, such as Aβ or Sup35 [39]. Besides the known effects of EGCG on amyloidogenic proteins associated with diseases, EGCG also binds to functional amyloids that perform physiological roles [40]. In this work, we intend to analyse the effect of EGCG on bacterial Hfq functional amyloid, with the aim to impede bacterial adaptation. Blocking the formation of Hfq-CTR using small molecules may indeed be a promising strategy for antibacterial development that may be used synergistically with conventional antibiotics.
2. Results

2.1. EGCG Remodels Hfq CTR Amyloid Fibrils

To investigate the possibility that Hfq functional amyloids can be remodeled in vitro, we screened the effect of EGCG on Hfq-CTR fibrils using transmission electron microscopy (TEM, see Section 4.3). In order to allow a statistical analysis on the sample, we used a negative staining procedure and not cryoTEM to reduce the length of acquisition. Note that thioflavin T staining is a widely used method to follow amyloids self-assembly. Nevertheless in the case of Hfq-CTR, thioflavin inhibits fibril formation and cannot be used [41]. As a model we first used the 11 amino acid residues peptide corresponding to the Hfq amyloid region only, referred to as Hfq CTR [42] (see sequence in Materials and Methods, Section 4.2). The effect of the EGCG’s potential amyloid interference was tested on preformed CTR_{11} fibrils (50 mg/mL). Fibrils were incubated in EGCG solutions (from 1 to 5 mM) for 24 h and examined by TEM (Figure 1). In the absence of the compound, the fibrils were abundant (Figure 1a), while incubation with 1 mM EGCG significantly reduced the amount of fibrils and led to formation of diffuse aggregates close to the fibrils (Figure 1b). At higher concentrations only rare fibrils can be observed (Figure 1c,d). This effect was confirmed with the 38 amino acid residues peptide corresponding to the full Hfq-CTR region (Figure 2). The corresponding peptide is referred to as Hfq CTR_{38} [34] (sequence in Materials and Methods, Section 4.2). TEM analyses did not allow for observing the total disappearance of CTR_{38} pre-formed fibrils when EGCG was added, in contrast to Hfq CTR_{11}. Nevertheless, we clearly see lower amount of fibrils, which confirms that EGCG also disrupts CTR_{38} fibrils, even if less efficiently than in the case of CTR_{11} (Figure 2a,b) Note that spontaneous self-assembly of CTR_{38} is significantly lower than for CTR_{11} (weeks vs days) and that CTR_{38} peptide has been incubated for a few weeks to assure self-assembly before adding EGCG for 24 h [34,43].

![Image of TEM visualization](image_url)

**Figure 1.** Transmission electron microscopy (TEM) visualisation of the effect of epigallocatechin-3-gallate (EGCG) on CTR_{11} preformed fibrils. (a) CTR_{11} without EGCG (control); (b) CTR_{11} with 1 mM EGCG; (c) CTR_{11} with 2.5 mM EGCG; (d) CTR_{11} with 5 mM EGCG; (e) EGCG 5 mM (no peptide). The presence of 1 mM EGCG is sufficient to dissociate the fibrils, even if the effect is not complete (incubation time 24 h). At 5 mM only a few fibrils remain on the grid (d). The images are representative of several tens of images that have been collected in each condition. Scale bars, 200 nm.

To know whether EGCG can inhibit the formation of new fibrils and not only disrupt pre-formed ones, its effect on the conversion of Hfq monomers into amyloid fibrils was also investigated. This analysis was not possible with CTR_{11}, as this peptide forms fibrils within a few hours and EGCG disrupts pre-formed fibrils in the same timeframe. We thus used Hfq CTR_{38} fibrils, which are more stable, for our analysis. To induce fibrillation of CTR_{38} within a shorter time (few days) we added DNA, which has been shown to accelerate fibril formation [43]. TEM analyses showed EGCG inhibition of the formation of Hfq CTR_{38} (Figure 2c,d). This indicates that EGCG does not only disrupt Hfq CTR preformed fibrils, but also inhibits their fibrillation.
Figure 2. Transmission electron microscopy (TEM) visualisation of the effect of epigallocatechin-3-gallate (EGCG) on CTR38 fibrils. Upper panel (a,b) pre-assembled fibrils of CTR38 alone; lower panel (c,d): fibrils of CTR38 formed in the presence of DNA. (a) CTR38 (control); (b) CTR38 with 5 mM EGCG; (c) CTR38 + DNA (control); (d): CTR38 + DNA with 5 mM EGCG. Incubation time with EGCG was 24 h. Scale bars, 200 nm.

2.2. Characterization of Hfq Amyloid Region Stability in the Presence of EGCG

We then analysed quantitatively the effect of EGCG on Hfq CTR stability. For this goal we used circular dichroism (CD). Precisely, we used synchrotron radiation circular dichroism (SRCD) for our analysis, which allows the wavelength range to be extended down to 170 nm for the identification and distinction of amyloid signals [44] (see Section 4.4.). Aggregation into β-sheets in an amyloidal structure implies significant SRCD spectral changes: inversion of the band at ~200 nm from a positive to a negative value (Figures 3 and 4); in parallel, a negative band decreases and shifts from ~225 nm to ~210 nm (Figure 3). The inversion of the band at ~200 nm and the blue-shift at 225 nm observed upon EGCG addition (5 mM, Figure 3) proves that the amyloid structure is disrupted by the compound, while the same peptide in the absence of the compound remains assembled. Precisely, in the presence of EGCG, relaxed antiparallel β-sheets (referred to as β anti 2, [45]) convert into right-handed twisted antiparallel β-sheets (referred to as β anti 3, [46]) (Table 1) [47].
**Figure 3.** CTR$_{11}$ disassembly in the presence of epigallocatechin-3-gallate (EGCG) 5 mM (black: 0 h and red: 4 h). Dissociation of the amyloid structure is observed by a shift of the negative peak from 226 to 212 nm [47]. The decrease of peak intensities also confirms disassembly. Path length = 1 µm, peptide concentration 12.5 mg/mL.

**Table 1.** CTR$_{11}$ secondary structure contents in the presence of epigallocatechin-3-gallate (EGCG) at 0 and 4 h determined using BestSel [47].

| Time (h) | Helix 1 | Helix 2 | Anti 1 | Anti 2 | Anti 3 | Para | Turn | Others | NRMSD |
|---------|---------|---------|--------|--------|--------|------|------|--------|-------|
| 0       | 0.0     | 0.60    | 10.6   | 13.6   | 0.00   | 10.8 | 17.4 | 46.9   | 0.04649 |
| 4       | 5.1     | 5.8     | 0      | 4.8    | 11.4   | 12.1 | 15.4 | 45.3   | 0.06050 |

Note that a similar effect is also observed with Hfq CTR$_{38}$, even if in this case the blue shift is less noticeable (not shown). To quantify this effect on CTR$_{11}$, we then analysed SRCD melting curves of preformed fibrils of CTR$_{11}$ in the presence of EGCG (Figure 4).

The respective secondary structure compositions at different temperatures were determined using BestSel and are reported in Table 2. As expected, at room temperature the peptide is partially folded into β-sheets, mainly in relaxed antiparallel β-sheets (β anti 2) [47]. Note that adding EGCG immediately results in the β anti 3 structure melting at 20 °C (Table 2).

**Figure 4.** Cont.
Figure 4. Melting curves of CTR11 fibrils, alone or in the presence of epigallocatechin-3-gallate (EGCG). (a,c,e) CTR11 alone; (b,d,f) CTR11 in the presence of EGCG 5 mM (substracted from EGCG signal). (a,b) Synchrotron radiation circular dichroism (SRCD) spectra measurements were carried out every 5 °C; blue 20 °C; red 95 °C (c,d): Measurement of the melting temperature at 176, 198 and 226 nm. The inversion of the band at 198 nm from a positive to a negative value is the signature of the conversion from relaxed antiparallel β-sheets (β anti 2) into right-handed twisted antiparallel β-sheets (β anti 3) [47] (Table 2). The melting temperatures measured from SRCD values at 198 nm are Tm = 62.0 ± 1 °C for CTR11 alone (c) and Tm = 55.6 ± 1 °C in the presence of EGCG (d). (e,f) Van’t Hoff’s plots giving access to ΔH° and ΔS° of CTR11 melting. The isosbestic point indicates a two state model and a Boltzmann sigmoid equation has been used for melting curves fitting.
When temperature increases, relaxed antiparallel β-sheets (β anti 2) convert into right-handed twisted antiparallel β-sheets (β anti 3) [47] (Table 2). The signature of this conversion is mainly observed at 198 nm (Figure 4a,b) [47]. We thus analysed the melting temperature of the assembly based on the SRCD signal at 198 nm. We confirmed the disrupting effect of epigallocatechin-3-gallate (EGCG) as melting temperature decreases significantly from Tm = 62 ± 1 to Tm = 55.6 ± 1 °C in the presence of EGCG (Figure 4b,d). The Tm in absence of EGCG was confirmed using differential scanning calorimetry (DSC) (Tm = 63.9 ± 1 °C, Supplementary Figure S1). DSC analysis in the presence of EGCG did not yield interpretable data as EGCG alone gives a DSC signal close to that of the peptide. Van’t Hoff’s plots were drawn from melting curves (Figure 4e,f), giving access to $\Delta H^\circ$ and $\Delta S^\circ$ of CTR11 fibrils disassembly in the absence or presence of EGCG. For CTR11 fibrils alone, $\Delta H^\circ = 75.06 \pm 4.5 \text{ kJ} \cdot \text{mol}^{-1}$ and $\Delta S^\circ = 0.225 \pm 0.13 \text{ kJ} \cdot \text{mol}^{-1} \cdot \text{K}^{-1}$, while for CTR11 in the presence of EGCG $\Delta H^\circ = 61.9 \pm 4.9 \text{ kJ} \cdot \text{mol}^{-1}$ and $\Delta S^\circ = 0.193 \pm 0.015 \text{ kJ} \cdot \text{mol}^{-1} \cdot \text{K}^{-1}$. In both cases, we confirm disassembly is an endothermic process. Furthermore, we confirm that fibrils are significantly less stable in the presence of EGCG.

### 2.3. EGCG Affects Bacterial Survival Due to Its Interaction with Hfq CTR

Finally, the effect of EGCG on bacterial survival has been evaluated. For this goal, different bacterial strains have been used, namely MG1655 WT cells [48], MG1655 Δhfq and MG1655 hfq72 (deleted for the last 90 hfq nucleotides giving a truncated protein with only the first 72 amino acids,
this strain can also be referred to as hfqΔctr, see Section 4.5.) [43]. As EGCG is a highly absorbing and fluorescent molecule with spectral properties depending on solvents [49], the use of bacterial viability kits based on fluorescence or colorimetric assay was not possible for this analysis [50]. The plate count method has thus been used to evaluate the concentration of the antimicrobial agent, here EGCG, which inhibits bacterial growth. Precisely, colony forming units (CFU) have been measured and the C50, the concentration of EGCG that decreases CFU by 50%, has been determined (see Section 4.6.). The C50 was 0.67 ± 0.02 mM for the WT strain vs 0.81 ± 0.05 mM for hfq72. Thus, the E. coli strain devoid of Hfq-CTR is less sensitive to EGCG than the WT strain. Note that due to the pleiotropic effect of the protein, the total absence of Hfq has a major effect on bacterial survival in the presence of EGCG (C50 ~0.4 ± 0.1 mM). This was expected as Hfq and sRNA establish resistance to various drugs, including antibiotics, in bacteria [9,18,51].

3. Discussion

Green tea polyphenolic catechins, including EGCG, have been shown to have antibacterial properties [52]. These properties arise from different mechanisms, including damage to bacterial cell membrane, inhibition of fatty acid synthesis, inhibition of enzyme activities (DNA gyrase, dihydrofolate reductase, etc) or act as an antibiofilm agent [53–56]. In this work we show that in addition to these roles, the EGCG catechin is also able to block the adaptability of bacteria when colonizing its host. Precisely, EGCG acts on the E. coli Hfq protein and inhibits its self-assembly [34]. Note that antibacterial effects reported previously for EGCG may be partially attributed to the inhibition of Hfq function, precisely in membrane and DNA-related processes or in biofilm formation [56–58].

In this work, we fully characterize the effect of EGCG on Hfq amyloid region self-assembly. As expected, we observe that Hfq-CTR amyloid disassembly is an endothermic process and we show that adding EGCG significantly decreases the enthalpy of the reaction (by ~20%). This suggests that EGCG acts on CTR11 oligomers mainly through disruption of hydrogen bonds. Hydrophobic interactions (entropy-driven) do not seem to be significantly involved. This is however not surprising taking into account the low number of hydrophobic amino acid residues present in the amyloidogenic region of Hfq [59]. Even if EGCG, the natural product, emerges as a promising new antibacterial agent against Gram-negative bacteria and exhibits alone antibacterial activity, this compound may be improved to more specifically and efficiently target the Hfq amyloid region. Catechins from other plants may alternatively be more specific. Otherwise, the galloyl moiety of EGCG could be chemically modified with the perspective of having more specific anti-Hfq properties [60]. Note that the in vitro inhibition concentration and C50 values we measured (in the mM range) are close to the minimal inhibitory concentration (MIC) reported for other Gram-negative bacteria (about 1 mM, [61,62]). MICs in Gram-negative bacteria are significantly higher than that in Gram-positive bacteria, probably due to protection by the outer membrane [62]. This C50 concentration is significantly higher than the equilibrium dissociation constant (Kd) of the EGCG/CTR11 complex, which is in the µM range (Supplementary Figure S2). This suggests that the property of EGCG that must be optimised is its disassembling efficiency, and not its binding to CTR11. Nevertheless, the precise 3D structure of this region of the protein is still unknown [23], and rational design of modified catechins to target Hfq-CTR is thus challenging.

4. Materials and Methods

4.1. Chemicals

All chemicals including EGCG were from Sigma-Aldrich. EGCG was prepared in milliQ water at 10 mM.
4.2. Hfq CTR Peptides

Hfq CTR\textsubscript{38} and CTR\textsubscript{11} peptide were chemically synthetized (Proteogenix SA) \cite{34}. Corresponding sequences were for CTR\textsubscript{38}: SRPVSHSNAGGTSSNYHGSAAQNTSAQQDSEETE, and for CTR\textsubscript{11}: SAQNTSAQQDS. The fibrils were obtained from a solution at 20 or 100 mg/mL incubated for days (CTR\textsubscript{11}) to weeks (CTR\textsubscript{38}). DNA-induced fibrillation was obtained in the presence of (dA:dT)\textsubscript{59} duplex (2 mM) (Eurogentec), as described in Malabirade et al. \cite{43}.

4.3. TEM Imaging of Protein Fibrils

EGCG was added to fibrils (final concentration from 1 to 5 mM). Except when specified, samples were incubated for 24 h and visualized by TEM. To perform negative staining, 5 \(\mu\)L of peptide sample was deposited on a glow-discharged carbon-coated electron microscopy copper grid (continuous carbon film on 200 mesh square copper grid, EMS). After 2 min, the excess of sample was blotted out using a Whatman filter paper. Then, 5 \(\mu\)L of contrasting agent solution (Gadolinium salt, uranyl-less) was applied onto the grid with peptide. After 1 min incubation, the excess of contrasting agent was blotted out and then the grids were kept in a dry dark dust-free environment until observation with the electron microscope. For sample observation, the electron microscopy grid was mounted onto a room temperature holder and introduced into a JEOL 2200FS electron microscope (JEOL, Tokyo, Japan). The TEM images (2048 \(\times\) 2048 pixels) were acquired using a Gatan UltraScan894 US1000 slow scan CCD camera at 40,000 \(\times\) nominal magnification (corresponding pixel size was 0.32 nm). The images presented in this work are representative of several tens of images that have been collected on 2 independent samples.

4.4. Synchrotron Radiation Circular Dichroism (SRCD)

For SRCD analysis, measurements and data collection were carried out on DISCO beam-line at the SOLEIL Synchrotron (proposal # 20180165) \cite{63}. Samples of 2-4 \(\mu\)L were loaded into circular demountable CaF\textsubscript{2} cells of 1 micron path length and analysed at different incubation time \cite{64}. Separated data collections were carried out to ensure repeatability. Spectral acquisitions of 1 nm steps at 1.2 integration time, between 320 and 180 nm were performed in triplicate for the samples as well as for the baselines. (+)-camphor-10-sulfonic acid (CSA) was used to calibrate amplitudes and wavelength positions of the SRCD experiment. Data-analyses including averaging, baseline subtraction, smoothing, scaling and standardization were carried out with CDtool. Secondary structure content was determined using BestSel \cite{47,65}. Normalized root-mean-square deviation (NRMSD) indicated the most accurate fit for each spectrum; values of <0.15 were considered significant. For melting curves, SRCD spectra were acquired every 5 °C between 20 °C and 95° C (in 1 micron path length cell) for CTR\textsubscript{11}, CTR\textsubscript{11} in the presence of EGCG and EGCG alone. SRCD values at 198 nm are presented as a function of temperature to measure the melting point (Tm). A Boltzmann sigmoid equation, which assumes a two state model, has been used for fitting of melting curves: \(y = \text{Bottom} + \frac{\text{top} - \text{bottom}}{1 + e((\text{Tm} - x)/\text{slope})}\). The energetics involved in self-assembly was determined by a van’t Hoff plot. Fractions of folded (\(f_\text{f}\)) or unfolded (\(f_\text{u}\)) structures were measured from melting curves. The equilibrium constant K was calculated as \(f_\text{f} / f_\text{u}\). \(\Delta G^\circ\) the effective change in standard free energy of reaction is defined as \(\Delta G^\circ = \Delta H^\circ - T\Delta S^\circ = -RT \ln K\), where \(\Delta H^\circ\) is the change in standard enthalpy of reaction, \(\Delta S^\circ\) the change in standard entropy of reaction, R the gaz constant and T the absolute temperature (expressed in Kelvin). \(\Delta S^\circ\) and \(\Delta H^\circ\) are extracted directly from the van’t Hoff plot where R lnK is plotted against 1/T (R lnK = \(\Delta S^\circ\) - \(\Delta H^\circ\) \times 1/T), with \(-\Delta H^\circ\) the slope and \(\Delta S^\circ\) the intercept at origin of the straight-line. Note that thermodynamic parameters may have an incertitude of \(-10\%\) due to the uncertainty for the lower and upper limit of the melting curves.
4.5. Construction of E. coli Strains

Strains were constructed with the λ-red recombination technique, as described in Malabirade et al. [43].

4.6. Effect of EGCG on E. coli Survival

The plate count method has been used to evaluate the efficiency of EGCG on bacterial EGCG. This method involves the incorporation of different concentrations of the antimicrobial substance into a LB agar medium followed by the application of a standardized number of cells to the surface of the agar plate [66]. Briefly in our case E. coli MG1655 strains were grown overnight in LB medium (37 °C at 120 rpm), diluted, and grown to an OD_{600} of 0.6. Diluted samples (from 10^{-5} to 10^{-7}) were plated on agar plates in triplicate after overnight incubation. The experiment was repeated twice with independent cultures. Colonies were counted to determine CFU, an estimate of viable bacteria. To ensure no colonies grow slowly, plates were kept at 37 °C for 2 extra days. The concentration of the assayed antimicrobial agent (here EGCG) that decreases CFU by 50% has been measured in each case to evaluate the activity of EGCG as an antimicrobial agent. This value is referred as C_{50} in this manuscript.

5. Conclusions

Natural or modified EGCG are already known to work synergistically with other antibiotics against E. coli, K. pneumoniae or A. baumanii isolates. Here we show that they may be used efficiently with conventional antibiotics (such as β-lactams or chloramphenicol) to block bacterial adaptation [67–70]. This should allow extending the spectrum of agents against multi-resistant and biofilm forming bacteria, and in general provide an efficient anti-infective compound, especially as EGCG has also antifungal and antiviral properties [71].

Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/7/4/95/s1, Figure S1: DSC analysis of Hfq-CTR11 melting. Figure S2: Hfq-CTR11/EGCG equilibrium dissociation constant measurement using ITC.

Author Contributions: Conceptualization, V.A. and F.W.; methodology, F.W., S.T.; software, F.W.; formal analysis, V.A., F.W.; investigation, D.P., F.T., O.E.H., C.C., M.B., S.T., F.W., V.A.; resources, V.A.; writing—original draft preparation, V.A.; writing—review and editing, V.A., S.T., F.W.; supervision, V.A., F.W.; project administration, V.A.

Funding: This work was supported by CNRS, CEA and synchrotron SOLEIL.

Acknowledgments: We are very grateful to Oriana Osta (LLB/CEA Saclay) for her help with DSC experiments, to My-An Tran and Jozsef Kardos for helping in ITC data-acquisition and interpretation, to Daniele Joseleau-Petit for many fruitful discussions, and to Florent Busi and Antoine Malabirade for critical reading of the manuscript. SRCD measurements on DISCO beamline at SOLEIL Synchrotron were performed under proposal # 20180165. We thank the PICT-Ibisa for providing access to the electron microscopy facility. We also thank ISMO for the access to ITC (Malvern) financed through RESPORE, DIM Poreux (Ile de France) AAP Equipements fédérateurs 2017.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Munita, J.M.; Arias, C.A. Mechanisms of Antibiotic Resistance. Microbiol. Spectr. 2016, 4. [CrossRef]
2. Poole, K. Stress responses as determinants of antimicrobial resistance in Gram-negative bacteria. Trends Microbiol. 2012, 20, 227–234. [CrossRef] [PubMed]
3. Dorman, C.J. Nucleoid-associated proteins and bacterial physiology. Adv. Appl. Microbiol. 2009, 67, 47–64. [CrossRef] [PubMed]
4. Badaut, C.; Williams, R.; Arluison, V.; Bouffartigues, E.; Robert, B.; Buc, H.; Rimsky, S. The degree of oligomerization of the H-NS nucleoid structuring protein is related to specific binding to DNA. J. Biol. Chem. 2002, 277, 41657–41666. [CrossRef] [PubMed]
5. Harrison, J.A.; Pickard, D.; Higgins, C.F.; Khan, A.; Chatfield, S.N.; Ali, T.; Dorman, C.J.; Hormaeche, C.E.; Dougan, G. Role of hns in the virulence phenotype of pathogenic salmonellae. *Mol. Microbiol.* 1994, 13, 133–140. [CrossRef] [PubMed]

6. Schechter, L.M.; Jain, S.; Akbar, S.; Lee, C.A. The small nucleoid-binding proteins H-NS, HU, and Fis affect hila expression in Salmonella enterica serovar Typhimurium. *Infect. Immun.* 2003, 71, 5432–5435. [CrossRef] [PubMed]

7. Porcheron, G.; Dozois, C.M. Interplay between iron homeostasis and virulence: Fur and RyhB as major regulators of bacterial pathogenicity. *Vet. Microbiol.* 2015, 179, 2–14. [CrossRef] [PubMed]

8. Cavita, K.; de Mets, F.; Gottesman, S. New aspects of RNA-based regulation by Hfq and its partner sRNAs. *Curr. Opin. Microbiol.* 2018, 42, 53–61. [CrossRef] [PubMed]

9. Zhang, Y.F.; Han, K.; Chandler, C.E.; Tjaden, B.; Ernst, R.K.; Lory, S. Probing the sRNA regulatory landscape of P. aeruginosa: Post-transcriptional control of determinants of pathogenicity and antibiotic susceptibility. *Mol. Microbiol.* 2017, 106, 919–937. [CrossRef] [PubMed]

10. Gottesman, S.; Storz, G. Bacterial small RNA regulators: Versatile roles and rapidly evolving variations. *Cold Spring Harb. Perspect. Biol.* 2011, 3. [CrossRef] [PubMed]

11. Storz, G.; Vogel, J.; Wassarman, K.M. Regulation by small RNAs in bacteria: Expanding frontiers. *Mol. Cell.* 2011, 43, 880–891. [CrossRef] [PubMed]

12. Aiba, H. Mechanism of RNA silencing by Hfq-binding small RNAs. *Curr. Opin. Microbiol.* 2007, 10, 134–139. [CrossRef] [PubMed]

13. Arluison, V.; Hohng, S.; Roy, R.; Pellegrini, O.; Regnier, P.; Ha, T. Spectroscopic observation of RNA chaperone activities of Hfq in post-transcriptional regulation by a small non-coding RNA. *Nucleic Acids Res.* 2007, 35, 999–1006. [CrossRef] [PubMed]

14. Storz, G.; Opdyke, J.A.; Zhang, A. Controlling mRNA stability and translation with small, noncoding RNAs. *Curr. Opin. Microbiol.* 2004, 7, 140–144. [CrossRef] [PubMed]

15. Sittka, A.; Pfeiffer, V.; Tedin, K.; Vogel, J. The RNA chaperone Hfq is essential for the virulence of Salmonella typhimurium. *Mol. Microbiol.* 2007, 63, 193–217. [CrossRef] [PubMed]

16. Feliciano, J.R.; Grilo, A.M.; Guerreiro, S.I.; Sousa, S.A.; Leitao, J.H. Hfq: A multifaceted RNA chaperone involved in virulence. *Future Microbiol.* 2016, 11, 137–151. [CrossRef] [PubMed]

17. Kendall, M.M.; Gruber, C.C.; Rasko, D.A.; Hughes, D.T.; Sperandio, V. Hfq virulence regulation in enterohemorrhagic *Escherichia coli* O157:H7 strain 86-24. *J. Bacteriol.* 2011, 193, 6843–6851. [CrossRef] [PubMed]

18. Dersch, P.; Khan, M.A.; Muhlen, S.; Gorke, B. Roles of Regulatory RNAs for Antibiotic Resistance in Bacteria and Their Potential Value as Novel Drug Targets. *Front. Microbiol.* 2017, 8, 803. [CrossRef] [PubMed]

19. El-Mowafi, S.A.; Alumasa, J.N.; Dougan, G. Role of Hfq in post-transcriptional regulation by a small non-coding RNA. *Nucleic Acids Res.* 2015, 43, 193–217. [CrossRef] [PubMed]

20. Wilusz, C.J.; Wilusz, J. Eukaryotic Lsm proteins: Lessons from bacteria. *Nat. Struct. Mol. Biol.* 2005, 12, 1033–1036. [CrossRef] [PubMed]

21. Wilusz, C.J.; Wilusz, J. Lsm proteins and Hfq: Life at the 3′ end. *RNA Biol.* 2013, 10, 592–601. [CrossRef] [PubMed]

22. Brennan, R.G.; Link, T.M. Hfq structure, function and ligand binding. *Curr. Opin. Microbiol.* 2007, 10, 125–133. [CrossRef] [PubMed]

23. Vogel, J.; Luini, B.F. Hfq and its constellation of RNA. *Nat. Rev. Microbiol.* 2011, 9, 578–589. [CrossRef] [PubMed]

24. Link, T.M.; Valentin-Hansen, P.; Brennan, R.G. Structure of Escherichia coli Hfq bound to polyriboadenylate RNA. *Proc. Natl. Acad. Sci. USA* 2009, 106, 19292–19297. [CrossRef] [PubMed]

25. Schumacher, M.A.; Pearson, R.F.; Moller, T.; Valentin-Hansen, P.; Brennan, R.G. Structures of the pleiotropic translational regulator Hfq and an Hfq- RNA complex: A bacterial Sm-like protein. *EMBO J.* 2002, 21, 3546–3556. [CrossRef] [PubMed]

26. Dimastrogiovanni, D.; Frohlich, K.S.; Bandrya, K.J.; Bruce, H.A.; Hohensee, S.; Vogel, J.; Luini, B.F. Recognition of the small regulatory RNA RydC by the bacterial Hfq protein. *eLife* 2014, 3. [CrossRef] [PubMed]

27. Jiang, K.; Zhang, C.; Gutuula, D.; Liu, F.; van Kan, J.A.; Lavelle, C.; Kubia, K.; Malabirade, A.; Lapp, A.; Arluison, V.; et al. Effects of Hfq on the conformation and compaction of DNA. *Nucleic Acids Res.* 2015, 43, 4332–4341. [CrossRef] [PubMed]
28. Malabirade, A.; Jiang, K.; Kubiak, K.; Diaz-Mendoza, A.; Liu, F.; van Kan, J.A.; Berret, J.F.; Arluison, V.; van der Maarel, J.R.C. Compaction and condensation of DNA mediated by the C-terminal domain of Hfq. *Nucleic Acids Res.* 2017, 45, 7299–7308. [CrossRef] [PubMed]

29. Sauer, E.; Weichenrieder, O. Structural basis for RNA 3′-end recognition by Hfq. *Proc. Natl. Acad. Sci. USA* 2011, 108, 13065–13070. [CrossRef] [PubMed]

30. Nikulin, A.; Stolboushkina, E.; Perederina, A.; Vassilieva, I.; Blaesi, U.; Moll, I.; Kachalova, G.; Yokoyama, S.; Vassylev, D.; Garber, M.; et al. Structure of Pseudomonas aeruginosa Hfq protein. *Acta Crystallogr. D Biol. Crystallogr.* 2005, 61, 141–146. [CrossRef] [PubMed]

31. Sauer, E.; Weichenrieder, O. Revised role for Hfq bacterial regulator on DNA topology. *Acta Crystallogr. D Biol. Crystallogr.* 2007, 63, 1081–1085. [CrossRef] [PubMed]

32. Stanek, K.A.; Patterson-West, J.; Randolph, P.S.; Mura, C. Crystal structure and RNA-binding properties of an Hfq homolog from the deep-branching Aquificae: Conservation of the lateral RNA-binding mode. *Acta Crystallogr. D Struct. Biol.* 2017, 73, 294–315. [CrossRef] [PubMed]

33. Arluison, V.; Mura, C.; Guzman, M.R.; Liquier, J.; Pellegrini, O.; Gingery, M.; Regnier, P.; Marco, S. Three-dimensional Structures of Fibrillar Sm Proteins: Hfq and Other Sm-like Proteins. *J. Mol. Biol.* 2006, 356, 86–96. [CrossRef] [PubMed]

34. Fortas, E.; Piccirilli, F.; Malabirade, A.; Militello, V.; Trepout, S.; Marco, S.; Taghbaldout, A.; Arluison, V. New insight into the structure and function of Hfq C-terminus. *Biosci. Rep.* 2015, 35. [CrossRef] [PubMed]

35. Taghbaldout, A.; Yang, Q.; Arluison, V. The Escherichia coli RNA processing and degradation machinery is compartmentalized within an organized cellular network. *Biochem.* J. 2014, 458, 11–22. [CrossRef] [PubMed]

36. Diestra, E.; Cayrol, B.; Arluison, V.; Risco, C. Membrane association of the bacterial riboregulator Hfq and functional perspectives. *Acta Crystallogr. D Biol. Crystallogr.* 2006, 62, 833–838. [CrossRef] [PubMed]

37. Guillier, M.; Gottesman, S.; Storz, G. Modulating the outer membrane with small RNAs. *Genes Dev.* 2006, 20, 2338–2348. [CrossRef] [PubMed]

38. Parker, A.; Gottesman, S. Small RNA Regulation of TolC, the Outer Membrane Component of Bacterial Multidrug Transporters. *J. Bacteriol.* 2016, 198, 1101–1113. [CrossRef] [PubMed]

39. Palhano, F.L.; Lee, J.; Grimster, N.P.; Kelly, J.W. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. *J. Am. Chem. Soc.* 2013, 135, 7503–7510. [CrossRef] [PubMed]

40. Maury, C.P. The emerging concept of functional amyloid. *J. Intern. Med.* 2009, 265, 329–334. [CrossRef] [PubMed]

41. Stains, C.I.; Mondal, K.; Ghosh, I. Molecules that target beta-amyloid. *ChemMedChem* 2007, 2, 1674–1692. [CrossRef] [PubMed]

42. Malabirade, A.; Morgado-Brajones, J.; Trepout, S.; Wien, F.; Marquez, I.; Seguin, J.; Marco, S.; Velez, M.; Arluison, V. Membrane association of the bacterial riboregulator Hfq and functional perspectives. *Sci. Rep.* 2017, 7, 10724. [CrossRef] [PubMed]

43. Malabirade, A.; Partouche, D.; El Hamoui, O.; Turbant, F.; Geinguenaud, F.; Recouvreux, P.; Bizien, T.; Busi, F.; Wien, F.; Arluison, V. Revised role for Hfq bacteria regulator on DNA topology. *Sci. Rep.* 2018, 8, 16792. [CrossRef] [PubMed]

44. Gobeaux, F.; Wien, F. Reversible assembly of a drug peptide into amyloid fibrils: A dynamic circular dichroism study. *Langmuir* 2018. [CrossRef] [PubMed]

45. Iwata, K.; Matsuura, T.; Sakurai, K.; Nakagawa, A.; Goto, Y. High-resolution crystal structure of betat-2-microglobulin formed at pH 7.0. *J. Biochem.* 2007, 142, 413–419. [CrossRef] [PubMed]

46. De Meester, P.; Brick, P.; Lloyd, L.F.; Blow, D.M.; Onesti, S. Structure of the Kunitz-type soybean trypsin inhibitor (STI): Implication for the interactions between members of the STI family and tissue-plasminogen activator. *Acta Crystallogr. D Biol. Crystallogr.* 1998, 54, 589–597. [CrossRef] [PubMed]

47. Micsonai, A.; Wien, F.; Bulyaki, E.; Kun, J.; Moussong, E.; Lee, Y.H.; Goto, Y.; Refregiers, M.; Kardos, J. BeStSel: A web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. *Nucleic Acids Res.* 2018, 46, W315–W322. [CrossRef] [PubMed]

48. Jensen, K.F. The *Escherichia coli* K-12 “wild types” W3110 and MG1655 have an rph frameshift mutation that leads to pyrimidine starvation due to low pyrE expression levels. *J. Bacteriol.* 1993, 175, 3401–3407. [CrossRef] [PubMed]
49. Snitsarev, V.; Young, M.N.; Miller, R.M.; Rotella, D.P. The spectral properties of (-)-epigallocatechin 3-O-gallate (EGCG) fluorescence in different solvents: Dependence on solvent polarity. *PloS ONE* **2013**, *8*, e79834. [CrossRef] [PubMed]

50. Davey, H.M. Life, death, and in-between: Meanings and methods in microbiology. *Appl. Environ. Microbiol.* **2011**, *77*, 5571–5576. [CrossRef] [PubMed]

51. Kim, T.; Bak, G.; Lee, J.; Kim, K.S. Systematic analysis of the role of bacterial Hfq-interacting sRNAs in the response to antibiotics. *J. Antimicrob. Chemother.* **2015**, *70*, 1659–1668. [CrossRef] [PubMed]

52. Reygaert, W.C. The antimicrobial possibilities of green tea. *Front. Microbiol.* **2014**, *5*, 434. [CrossRef] [PubMed]

53. Cui, Y.; Oh, Y.J.; Lim, J.; Youn, M.; Lee, I.; Pak, H.K.; Park, W.; Jo, W.; Park, S. AFM probing of the differential inhibitory effects of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) against Gram-positive and Gram-negative bacteria. *Food Microbiol.* **2012**, *29*, 80–87. [CrossRef] [PubMed]

54. Gradisar, H.; Pristovsek, P.; Plaper, A.; Jeralia, R. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. *J. Med. Chem.* **2007**, *50*, 264–271. [CrossRef] [PubMed]

55. Navarro-Martinez, M.D.; Navarro-Peran, E.; Cabezas-Herrera, J.; Ruiz-Gomez, J.; Garcia-Canovas, F.; Rodriguez-Lopez, J.N. Antifolate activity of epigallocatechin gallate against Stenotrophomonas maltophilia. *Antimicrob. Agents Chemother.* **2005**, *49*, 2914–2920. [CrossRef] [PubMed]

56. Serra, D.O.; Mika, F.; Richter, A.M.; Hengge, R. The green tea polyphenol EGCG inhibits E. coli biofilm formation by impairing amyloid amyloid fibre assembly and downregulating the biofilm regulator CsgD via the sigma(E) -dependent sRNA RybB. *Mol. Microbiol.* **2016**, *101*, 136–151. [CrossRef] [PubMed]

57. Klein, G.; Raina, S. Regulated Control of the Assembly and Diversity of LPS by Noncoding sRNAs. *BioMed Res. Int.* **2015**, *2015*, 153561. [CrossRef] [PubMed]

58. Cech, G.M.; Szalewska-Palasz, A.; Kubiak, K.; Malabirade, A.; Grange, W.; Arluison, V.; Wegrzyn, G. The Escherichia Coli Hfq Protein: An Unattended DNA-Transactions Regulator. *Front. Mol. Biosci.* **2016**, *3*, 36. [CrossRef] [PubMed]

59. Wang, S.H.; Liu, F.E.; Dong, X.Y.; Sun, Y. Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate. *J. Phys. Chem. B* **2010**, *114*, 11576–11583. [CrossRef] [PubMed]

60. Nakano, S.; Megro, S.I.; Hase, T.; Suzuki, T.; Isemura, M.; Nakamura, Y.; Ito, S. Computational Molecular Docking and X-ray Crystallographic Studies of Catechins in New Drug Design Strategies. *Molecules* **2018**, *23*. [CrossRef] [PubMed]

61. Lee, S.; Razqan, G.S.; Kwon, D.H. Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with beta-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii. *Phytotherapy Research* **2017**, *24*, 49–55. [CrossRef] [PubMed]

62. Jeon, J.; Kim, J.H.; Lee, C.K.; Oh, C.H.; Song, H.J. The Antimicrobial Activity of (-)-Epigallocatechin-3-Gallate and Green Tea Extracts against Pseudomonas aeruginosa and Escherichia coli isolated from Skin Wounds. *Ann. Dermatol.* **2014**, *26*, 564–569. [CrossRef] [PubMed]

63. Refregiers, M.; Wien, F.; Ta, H.P.; Premvarsdhan, L.; Bac, S.; Jamme, F.; Rouam, V.; Lagarde, B.; Polack, F.; Giorgetta, J.L.; et al. DISCO synchrotron-radiation circular-dichroism endstation at SOLEIL. *J. Synchrotron. Radiat.* **2012**, *19*, 831–835. [CrossRef] [PubMed]

64. Wien, F.; Wallace, B.A. Calcium fluoride micro cells for synchrotron radiation circular dichroism spectroscopy. *Appl. Spectrosc.* **2005**, *59*, 1109–1113. [CrossRef] [PubMed]

65. Micsonai, A.; Wien, F.; Kernya, L.; Lee, Y.H.; Goto, Y.; Refregiers, M.; Kardos, J. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, E3095–E3103. [CrossRef] [PubMed]

66. Wiegand, I.; Hilpert, K.; Hancock, R.E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat. Protoc.* **2008**, *3*, 163–175. [CrossRef] [PubMed]

67. Cui, Y.; Kim, S.H.; Cui, Y.; Yeom, J.; Ko, K.; Park, W.; Park, S. AFM probing of the mechanism of synergistic effects of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) with cefotaxime against extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli*. *PloS ONE* **2012**, *7*, e48880. [CrossRef] [PubMed]

68. Cho, Y.S.; Oh, J.J.; Oh, K.H. Synergistic anti-bacterial and proteomic effects of epigallocatechin gallate on clinical isolates of imipenem-resistant Klebsiella pneumoniae. *Phytomedicine* **2011**, *18*, 941–946. [CrossRef] [PubMed]
69. Zhao, W.H.; Asano, N.; Hu, Z.Q.; Shimamura, T. Restoration of antibacterial activity of beta-lactams by epigallocatechin gallate against beta-lactamase-producing species depending on location of beta-lactamase. *J. Pharm. Pharmacol.* 2003, 55, 735–740. [CrossRef] [PubMed]

70. Fanaki, N.H.; Kassem, M.A.; Fawzi, M.A.; Dabbous, F.; El-Nakeeb, M.A. Influence of aqueous green tea extract on the antimicrobial activity of some antibiotics against multiresistant clinical isolates. *Egypt. J. Med. Microbiol.* 2008, 17, 449–460.

71. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. *Br. J. Pharmacol.* 2013, 168, 1059–1073. [CrossRef] [PubMed]